Zavaglia. C C; Severini. R R; Tinelli. C C; Franzone. J S JS; Airoldi. A A; Tempini. S S; Bettale. G...
In a small trial of 44 chronic hepatitis B patients without the protective anti‑HBe antibody, giving thymosin‑alpha‑1 for six months didn’t cure the infection or dramatically improve viral markers compared with doing nothing, but it was safe and seemed to keep liver enzymes (ALT) lower, suggesting a modest anti‑inflammatory effect.
Moscarella. S S; Buzzelli. G G; Romanelli. R G RG; Monti. M M; Giannini. C C; Careccia. G G; Marrocc...
In a small trial, adding the immune‑boosting peptide thymosin‑alpha‑1 to standard interferon treatment helped more hepatitis C patients clear the virus and normalize liver enzymes by the end of therapy, though the long‑term benefit was only a little better.
Ni. Chao C; Wu. Pin P; Wu. Xianguo X; Zhang. Ting T; Zhang. Tao T; Wang. Zhen Z; Zhang. Sai S; Qiu....
The study shows that the peptide thymosin‑alpha‑1 can make colon cancer cells more visible to a special type of immune cell (iNKT cells) by increasing a molecule called CD1d on the cancer cells, which leads to stronger killing of the cancer cells in lab and mouse experiments.
The paper says that standard hepatitis C treatment with interferon isn’t great, and things like excess iron in the liver make it work even worse. Removing iron or using antioxidants like N‑acetyl‑cysteine can help the liver’s health and may boost interferon’s effect. Thymosin‑alpha‑1, a protein that tweaks the immune system, looks promising but only tiny studies have looked at it, so there’s no solid recipe yet.
Sasaki. H H; Fujii. Y Y; Masaoka. A A; Yamakawa. Y Y; Fukai. I I; Kiriyama. M M; Saito. Y Y; Matsui....
Researchers measured the blood level of the peptide thymosin‑alpha‑1 in people with lung cancer and found that, on average, it was higher than in healthy folks, but half the patients had normal levels. The amount didn’t track with tumor stage, didn’t fall after the tumor was removed, and higher levels were linked to worse survival, especially if the person also had another cancer. So the peptide might serve as a warning sign rather than a treatment tool.
This review explains that the thymus and pituitary glands normally communicate, but aging weakens that connection. Thymic hormones like thymosin‑alpha‑1 can influence hormones such as ACTH, cortisol, and reproductive hormones in animals, though older animals show a blunted response. The paper suggests the shrinking thymus may be an early trigger of broader age‑related hormonal decline.
The paper mainly discusses interferon and lamivudine for chronic hepatitis B and only mentions thymosin‑alpha‑1 as an approved drug in a few countries, without detailed results. There’s no clear dosing or strong evidence that thymosin alone works, so it’s not a ready‑to‑use protocol for self‑experimenters.
The paper shows that the immune‑boosting peptide thymosin‑alpha‑1 looks a lot like interferon‑alpha at the molecular level, and they can both bind similar receptors. Because of this, lab‑made interferon‑alpha can copy some of thymosin‑alpha‑1’s effects, like helping vaccines work better, and scientists are even trying to graft thymosin‑like parts onto new proteins. However, the study is mostly about basic biology, not dosing or safe DIY use.
The review says that while many antiviral drugs work against hepatitis B, the immune‑boosting peptide thymosin‑alpha‑1 (thymalfasin) hasn’t shown enough benefit to be used widely, so it’s not a useful tool for treating HBV on its own.
Scientists figured out a way to make the immune‑boosting peptide thymosin‑alpha‑1 inside bacteria, getting it properly acetylated and very pure, which could be a cheaper alternative to chemical synthesis.
Yared. G G; Hussain. K B KB; Nathani. M G MG; Moshier. J A JA; Dosescu. J J; Mutchnick. M G MG; Nayl...
The study shows that thymosin‑alpha‑1 (Tα1) by itself does little to kill liver cells infected with hepatitis B or to stop the virus from making copies, but when it’s combined with interferon‑alpha it significantly cuts down virus production in a lab dish. Tα1 also only slows the growth of hepatitis‑B‑infected liver cells, not other virus‑transformed cells. These results are from cell‑culture experiments, not human trials.
A study found that the peptide thymosin‑alpha‑1 can boost how well human sperm penetrate an egg‑like target, mainly by helping the sperm undergo the acrosome reaction, which is needed for fertilization. Men with infertility had lower levels of this peptide in their semen, suggesting a link. However, the research is early‑stage, done in lab assays, and doesn’t give dosing or safety info for everyday use.
Thymosin alpha-1 is a short peptide that seems safe up to fairly high doses and might help keep certain cancers from coming back, but the evidence is still weak and the best dose schedule isn’t clear yet, so it’s not ready for regular use.
Gökkusu. C C; Ademoğlu. E E; Türkoğlu. U M UM; Oz. H H; Oz. F F
In a rabbit study, giving thymosin‑alpha‑1 helped bring blood fats back to normal, lowered harmful oxidative damage in the liver and aorta, and boosted the antioxidant glutathione, suggesting it might protect against artery disease, though it’s only animal data.
Di Francesco. P P; Pica. F F; Marini. S S; Favalli. C C; Garaci. E E
In mice, the immune‑boosting peptide thymosin‑alpha‑1 helped reverse the damage to immune cells caused by cocaine use, speeding up recovery of natural killer cells and restoring key T‑cell functions and cytokine levels.
In rats, giving thymosin‑alpha‑1 directly into the brain lowered blood levels of thyroid‑stimulating hormone, stress hormone ACTH, and prolactin, while not changing growth hormone. When pituitary tissue was exposed to the peptide in a dish, it actually boosted the release of TSH and ACTH. These mixed results come from animal studies using brain injections, not the typical skin‑injection used by most people.
Tuthill. Cynthia C; Rios. Israel I; McBeath. Randy R
Thymosin alpha‑1 is a peptide that was first found to help rebuild the immune system in animals without a thymus. Over the past few decades it has been tested in many clinical studies, from tiny early trials in people with immune deficiencies to large phase‑3 trials in the US, Italy, China and elsewhere. The research shows it is generally safe and has been explored for many health conditions, but the abstract doesn’t give new dosing tips or clear performance benefits for everyday use.
Garaci. E E; Pica. F F; Mastino. A A; Palamara. A T AT; Belardelli. F F; Favalli. C C
In mice with a fast‑growing blood cancer, giving thymosin‑alpha‑1 together with tiny amounts of IL‑2 or interferon and a low dose of the chemo drug cyclophosphamide made the tumors disappear and helped the animals live longer. The effect only happened when the three were combined and relied on immune cells like CD4, CD8 and NK cells.
di Francesco. P P; Gaziano. R R; Casalinuovo. I A IA; Belogi. L L; Palamara. A T AT; Favalli. C C; G...
In a mouse study, giving the immune‑boosting peptide thymosin‑alpha‑1 together with the antifungal drug fluconazole helped mice that were weakened by morphine survive longer and clear a Candida infection better than either treatment alone.
A new combined peptide made from thymosin‑α1 and thymopentin (called Tα1‑TP5) helped mice recover from drug‑induced immune suppression and worked better with a chemotherapy drug to slow tumor growth. It also sticks to a immune sensor called TLR2 more strongly than thymosin‑α1 alone.